CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$11.2M
(+4.7%)
Cap. Flow
+$8.56M
Cap. Flow
% of AUM
3.44%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
266
Reduced
45
Closed
121
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Kezar Life Sciences
KZR
$28M
| $4.89K | ﹤0.01% |
70
+6
| +9% | +$419 |
|
|
KLRS
302
Kalaris Therapeutics, Inc. Common Stock
KLRS
$87.2M
| $4.86K | ﹤0.01% |
41
+3
| +8% | +$355 |
|
303
Scholar Rock
SRRK
$3.12B
| $4.75K | ﹤0.01% |
525
+42
| +9% | +$380 |
|
304
Phathom Pharmaceuticals
PHAT
$851M
| $4.75K | ﹤0.01% |
423
+56
| +15% | +$628 |
|
305
Sutro Biopharma
STRO
$86.5M
| $4.71K | ﹤0.01% |
583
+95
| +19% | +$768 |
|
306
ALX Oncology
ALXO
$57.8M
| $4.67K | ﹤0.01% |
414
+32
| +8% | +$361 |
|
307
Esperion Therapeutics
ESPR
$510M
| $4.67K | ﹤0.01% |
749
+126
| +20% | +$785 |
|
|
PSTX
308
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $4.63K | ﹤0.01% |
874
+70
| +9% | +$371 |
|
309
Arcturus Therapeutics
ARCT
$455M
| $4.56K | ﹤0.01% |
269
+20
| +8% | +$339 |
|
310
ATAI Life Sciences
ATAI
$977M
| $4.48K | ﹤0.01% |
1,685
+170
| +11% | +$452 |
|
|
AVDL
311
Avadel Pharmaceuticals
AVDL
$1.46B
| $4.43K | ﹤0.01% |
618
+66
| +12% | +$473 |
|
312
Nektar Therapeutics
NKTR
$684M
| $4.32K | ﹤0.01% |
127
+10
| +9% | +$340 |
|
313
Evolus
EOLS
$486M
| $4.29K | ﹤0.01% |
571
+46
| +9% | +$345 |
|
314
Vanda Pharmaceuticals
VNDA
$274M
| $4.25K | ﹤0.01% |
575
+45
| +8% | +$333 |
|
315
MacroGenics
MGNX
$123M
| $4.19K | ﹤0.01% |
624
+49
| +9% | +$329 |
|
|
NGM
316
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $4.17K | ﹤0.01% |
830
+78
| +10% | +$392 |
|
317
Harrow
HROW
$1.34B
| $4.1K | ﹤0.01% |
278
+25
| +10% | +$369 |
|
318
Atea Pharmaceuticals
AVIR
$264M
| $4.07K | ﹤0.01% |
846
+66
| +8% | +$317 |
|
319
PMV Pharmaceuticals
PMVP
$76.3M
| $4.04K | ﹤0.01% |
464
+37
| +9% | +$322 |
|
320
XPeng
XPEV
$18.9B
| $3.98K | ﹤0.01% |
400
-4,400
| -92% | -$43.7K |
|
321
Tarsus Pharmaceuticals
TARS
$2.42B
| $3.97K | ﹤0.01% |
+271
| New | +$3.97K |
|
322
Inovio Pharmaceuticals
INO
$146M
| $3.96K | ﹤0.01% |
211
+16
| +8% | +$300 |
|
323
Terns Pharmaceuticals
TERN
$618M
| $3.9K | ﹤0.01% |
383
+30
| +8% | +$305 |
|
324
Caribou Biosciences
CRBU
$172M
| $3.89K | ﹤0.01% |
620
+50
| +9% | +$314 |
|
325
Adicet Bio
ACET
$59.4M
| $3.89K | ﹤0.01% |
435
+60
| +16% | +$536 |
|